Pmv Pharmaceuticals Stock Revenue
| PMVP Stock | USD 1.27 0.01 0.79% |
Pmv Pharmaceuticals fundamentals help investors to digest information that contributes to Pmv Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Pmv Stock. The fundamental analysis module provides a way to measure Pmv Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pmv Pharmaceuticals stock.
| Last Reported | Projected for Next Year |
Pmv | Revenue |
Pmv Pharmaceuticals Company Revenue Analysis
Pmv Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Pmv
Projected quarterly revenue analysis of Pmv Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Pmv Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Pmv Pharmaceuticals' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Pmv Pharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Pmv Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pmv Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pmv Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Pmv Pharmaceuticals by comparing valuation metrics of similar companies.Pmv Pharmaceuticals is currently under evaluation in revenue category among its peers.
Pmv Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Pmv Pharmaceuticals from analyzing Pmv Pharmaceuticals' financial statements. These drivers represent accounts that assess Pmv Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pmv Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 2.8B | 1.0B | 396.7M | 77.9M | 89.6M | 85.1M | |
| Enterprise Value | 2.4B | 881.4M | 302.4M | 38.2M | 43.9M | 41.7M |
Pmv Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Pmv Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pmv Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pmv Pharmaceuticals' value.| Shares | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 539.9 K | Stonepine Capital Management Llc | 2024-12-31 | 535.8 K | Citigroup Inc | 2024-12-31 | 514.9 K | Two Sigma Investments Llc | 2024-12-31 | 507 K | Aldebaran Capital Llc | 2024-12-31 | 502.2 K | Peapod Lane Capital Llc | 2024-12-31 | 445.7 K | Geode Capital Management, Llc | 2024-12-31 | 421.7 K | M&t Bank Corp | 2024-12-31 | 399.5 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 370.9 K | Orbimed Advisors, Llc | 2024-12-31 | 6.5 M | Sio Capital Management, Llc | 2024-12-31 | 3.6 M |
Pmv Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | (102.83 M) | ||||
| Shares Outstanding | 51.93 M | ||||
| Shares Owned By Insiders | 2.48 % | ||||
| Shares Owned By Institutions | 81.35 % | ||||
| Number Of Shares Shorted | 864.66 K | ||||
| Price To Book | 0.37 X | ||||
| EBITDA | (85.45 M) | ||||
| Net Income | (58.71 M) | ||||
| Cash And Equivalents | 277.43 M | ||||
| Cash Per Share | 6.08 X | ||||
| Total Debt | 1.19 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 24.76 X | ||||
| Book Value Per Share | 3.39 X | ||||
| Cash Flow From Operations | (51.28 M) | ||||
| Short Ratio | 8.38 X | ||||
| Earnings Per Share | (1.14) X | ||||
| Price To Earnings To Growth | (0.31) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 47 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 65.44 M | ||||
| Total Asset | 191.29 M | ||||
| Retained Earnings | (368.71 M) | ||||
| Working Capital | 161.29 M | ||||
| Net Asset | 191.29 M |
About Pmv Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pmv Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pmv Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pmv Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Pmv Stock Analysis
When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.